×

Method of treating patients with hepatorenal syndrome type 1

  • US 10,335,452 B2
  • Filed: 10/22/2015
  • Issued: 07/02/2019
  • Est. Priority Date: 10/24/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating type 1 hepatorenal syndrome (HRS-1), the method comprising:

  • identifying a plurality of patients as having HRS-1;

    determining that a first patient of the plurality exhibits at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS);

    (i) a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3,(ii) a heart rate of greater than 90 beats per minute (BPM), and(iii) either a partial pressure of carbon dioxide in the blood (PaCO2)<

    32 mmHg or a blood bicarbonate (HCO3) level<

    23 mmol/L;

    determining that the first patient does not have overt sepsis, septic shock, or uncontrolled infection;

    determining that, because the first patient exhibits at least two of the three criteria and does not have overt sepsis, septic shock, or uncontrolled infection, the HRS-1 of the first patient is likely to respond to treatment with terlipressin;

    administering to the first patient an amount of terlipressin effective to treat HRS-1 in the first patient;

    determining that a second patient of the plurality exhibits only one or none of the three criteria or has overt sepsis, septic shock, or uncontrolled infection;

    determining that, because the second patient does not exhibit at least two of the three criteria or has overt sepsis, septic shock, or uncontrolled infection, the HRS-1 of the second patient is unlikely to respond to treatment with terlipressin;

    excluding the second patient from treatment with terlipressin determining that a third patient of the plurality has overt sepsis, septic shock, or uncontrolled infection; and

    excluding the third patient from treatment with terlipressin.

View all claims
  • 16 Assignments
Timeline View
Assignment View
    ×
    ×